SINGAPORE, Sept. 19, 2024 /PRNewswire/ — Markel, the insurance operations within Markel Group Inc. (NYSE: MKL), is pleased to announce the appointment of April Tam as Senior Underwriter, Professional Financial Risk (PFR) & Cyber and Head of Financial Institutions in Asia. This strategic hire is integral to advancing Markel’s profile and reinforcing its leadership position in the PFR sector.

April Tam, Senior Underwriter, Professional Financial Risk (PFR) and Head of Financial Institutions in Asia

In her new role, Tam will be instrumental in strengthening Markel’s Financial Institutions proposition in Asia. Working in collaboration with the regional underwriting team across Asia, Tam will focus on driving continued profitable growth of the company’s PFR book and ensuring its scalability and diversification. She will also be responsible for forging strong relationships with insurance brokers, clients and partners in the region.

Tam joins Markel from Allianz Commercial, where she was most recently employed as Financial Institutions Practice Leader, Asia. Prior to joining Allianz Commercial in 2018, Tam gained expertise at Zurich Insurance Group. With more than 12 years’ experience in Financial Lines underwriting, Tam brings a wealth of expertise, broker relationships and a proven track record to Markel.

Based in Hong Kong, Tam will report to Kevin Leung, Chief Underwriting Officer, Asia Pacific.

Leung commented: "I’m excited to welcome April to our team in Hong Kong. Her extensive experience and deep understanding of Financial Lines underwriting will be of huge importance as we continue to expand and enhance our PFR offerings. I’m confident that April’s expertise and strong networks will significantly help to contribute to our strategic objectives and strengthen our position in the Asia market."

About Markel
We are Markel, a leading global specialty insurer with a truly people-first approach. As the insurance operations within Markel Group Inc. (NYSE: MKL), we operate the Markel Specialty, Markel International, and Markel Global Reinsurance divisions, as well as State National, our portfolio protection and program services operations, and Nephila, our insurance-linked securities operations. Our broad array of capabilities and expertise allow us to create intelligent solutions for the most complex risk management needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.

Source : Markel appoints April Tam as Senior Underwriter, PFR & Cyber and Head of Financial Institutions, Asia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

RWE has secured the ammonia for its global supply portfolio for delivery from 2027 The green ammonia produced at AM Green Ammonia’s sites in India meets EU standards for Renewable Fuels from Non-Biological Origin (RFNBO), as defined in the RED III

ESSEN, Germany and HYDERABAD, India, Sept. 19, 2024 /PRNewswire/ — RWE Supply & Trading has signed a Memorandum of Understanding (MoU) with AM Green Ammonia B.V. (AMG) for the long-term supply of green ammonia from its plants based in India. It outlines the supply of up to 250,000 tonnes of green ammonia per year. The ammonia will be sourced from AMG’s production sites in Kakinada and Tuticorin, India. Initially, 50,000 tonnes of green ammonia will be produced at the Kakinada site, with the remaining volume of up to 200,000 tonnes to be sourced from the Tuticorin facility.

Ammonia Production Facility and Port Infrastructure on East Coast of India

AMG is a subsidiary of the AM Green Group. AMG’s ammonia manufacturing facilities will be powered entirely by carbon-free energy sources such as solar, wind, and hydroelectric power. The produced ammonia will meet EU standards for Renewable Fuels of Non-Biological Origin (RFNBO) as defined in the Renewable Energy Directive (RED III). AMG’s facility in Kakinada has already been pre-certified for RFNBO compliance. Pre-certification for other facilities is underway.

Deliveries of green ammonia from AMG’s sites are expected to start by 2027. A subsequent offtake agreement between RWE and AMG will detail the contractual provisions.

Costas Papamantellos, Head of International Hydrogen Investments at RWE Supply & Trading said, "RWE is committed to investing in hydrogen and its low-carbon derivatives to help industries achieve their climate goals. For this end, we are building strong supply chains with partners globally. Partnering with AMG allows us to secure green ammonia capacities at an early stage."

Mahesh Kolli, Group President of AM Green said, "We are delighted to partner with RWE to propel the transformation of various industries and several OECD economies. This agreement emphasizes AM Green’s ability to align itself with an innovative and flexible contracting structure in line with commodity trading practices. Continuous focus on innovation combined with execution reinforces AM Green’s leadership position as a global clean energy transition solutions platform for low-cost green molecules such as hydrogen, ammonia, fuels and other chemicals."

For further enquiries:

Olaf Winter

Suheil Imtiaz

Media Relations

Public Affairs & Strategic Communications

RWE Supply & Trading GmbH

AM Green

T: +49 201 5179-8455

M: + 91 94401 59289

E: [email protected]

E: [email protected]

Note to the editor – RWE Supply & Trading

RWE Supply & Trading is the interface between RWE and the energy markets around the world. Approximately 2,000 employees from over 70 different countries trade electricity, gas, commodities, and CO2 emission allowances. Accurate market analyses and a high degree of customer centricity enable them to create innovative energy supply solutions as well as risk management concepts for industrial operations. The trading entity also ensures the commercial optimisation of RWE’s power plant dispatch and markets electricity from RWE. In addition, there is the legally independent RWE gas storage business in Germany under the umbrella of RWE Supply & Trading.

RWE Supply & Trading is establishing itself as a key player in the global hydrogen market, focusing on green and blue hydrogen and their derivatives, such as ammonia. As part of its global strategy, the company is investing along the entire value chain by developing a diversified portfolio of projects and long-term offtake agreements worldwide, with a particular emphasis on importing green molecules to Northwest Europe.

Forward-looking statements

This press release contains forward-looking statements. These statements reflect the current views, expectations and assumptions of management, and are based on information currently available to management. Forward-looking statements do not guarantee the occurrence of future results and developments and are subject to known and unknown risks and uncertainties. Actual future results and developments may deviate materially from the expectations and assumptions expressed in this document due to various factors. These factors primarily include changes in the general economic and competitive environment. Furthermore, developments on financial markets and changes in currency exchange rates as well as changes in national and international laws, in particular in respect of fiscal regulation, and other factors influence the company’s future results and developments. Neither the company nor any of its affiliates undertakes to update the statements contained in this press release.

Data Protection

The personal data processed in connection with the press releases will be processed in compliance with the legal data protection requirements. If you are not interested in continuing to receive the press release, please inform us at [email protected]. Your data will then be deleted, and you will not receive any further press releases from us in this regard. If you have any questions about our data protection policy or the exercise of your rights under the GDPR, please contact [email protected].

Source : RWE and AM Green Ammonia sign Memorandum of Understanding to supply up to 250,000 tonnes annually of RFNBO-compliant ammonia from India

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Sept. 19, 2024 /PRNewswire/ — Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a Phase 1 study". The update data from ABSK-011-101 study showed a tolerable safety profile and promising anti-tumor activity of Irpagratinib monotherapy in aHCC. Of note, in aHCC patients who were pretreated with both immune checkpoint inhibitor (ICI) and Tyrosine Kinase Inhibitor (TKI)—a population with high unmet need in the current treatment paradigm—the observed ORR and DCR was 44.8% and 79.3%, respectively, with a median duration of response (mDoR) of 7.4 months and median progression free survival (mPFS) of 5.5 months.

The poster, #983P, was presented at the Hepatocellular Carcinoma poster session on Sunday, September 16, 2024. The Best Poster Award was given at the conclusion of the Sunday Poster Session, with only one recipient being honored in HCC poster session.

2024 ESMO Congress

As of September 5, 2024, 122 patients have been enrolled, including 74 in the BID cohort with doses consisting of 160mg BID, 220mg BID, and 300mg BID. 5.4% of patients were BCLC Stage B, and 89.2% BCLC Stage C, 64.9% had a Child-Pugh (CP) Score of 5, 27% CP Score of 6, and 6.8% CP Score of 7. 64.9% of patients received multiple lines of prior therapy, 85.1% of patients had previously been treated with ICIs, and 75.7% of patients had previously been treated with both ICIs and mTKIs.

The efficacy data show that forty pre-treated HCC patients with FGF19 overexpression were treated with irpagratinib 220 mg BID. Among the 38 evaluable patients, the response rate was 36.8% (14/38), and the disease control rate (DCR) was 78.9% (30/38). The response rate from the subset of patients who had previously received ICI and mTKI therapy was 44.8% (13/29). The longest observed DoR was 16.4 months and the mDoR was 7.4 months. DCR was 79.3% (23/29). mPFS was 5.5 months.

Safety data show one dose-limiting toxicity (DLT) was observed in the 300 mg BID cohort. The most common treatment-related adverse effects (TRAEs, >20%) were ALT elevation, diarrhea, AST elevation, hyperphosphatemia, bilirubin elevation, alkaline phosphatase elevation, platelet decrease, and total bile acid elevation. Grade 3-4 treatment-related adverse events (>5%) included AST elevation, ALT elevation, and diarrhea. No grade 5 adverse events occurred.

HCC is the main type of liver cancer, accounting for 85% to 90% of primary liver cancers.  HCC is highly malignant, about 30% of which have abnormally high FGFR4 expression and a poor prognosis, and the existing treatment methods still cannot meet the long-term survival benefits.  Currently, there is no approved standard of care for HCC patients who have progressed from first-line ICI-based therapies. The FGF19/FGFR4 signaling axis could be a novel therapeutic target for HCC. ABSK-011, a potent FGFR4 inhibitor, demonstrated a tolerable safety profile and promising anti-tumor activity as a single agent. Notably, the irpagratinib 220mg BID regimen exhibited a 44.8% ORR, 7.4 months mDoR and 5.5 months mPFS in heavily pre-treated HCC patients who had received both ICI and mTKI therapy, supporting further late-stage development of irpagratinib in such populations with substantial unmet medical need.

In addition, the design of the phase II study of pimicotinib in combination with chemotherapy and with/without toripalimab as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC) has been presented.

About Irpagratinib (ABSK011)

Irpagratinib is a highly selective FGFR4 small molecule inhibitor intended for the treatment of advanced solid tumors that present with abnormalities in the FGF19/FGFR4 signaling pathway (e.g., ligand FGF19 amplification/overexpression, FGFR4 mutation/amplification/fusion), including advanced HCC, cholangiocarcinoma, breast cancer, among others. The FGFR4 signaling pathway is a recognized and promising target for treating HCC. Clinical data with irpagratinib have demonstrated improved potency and anti-tumor efficacy, among other favorable therapeutic properties, compared to competitors.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to the discovery and development of innovative medicines that treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology. Please visit www.abbisko.com for more information.

Source : Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

MELBOURNE, Australia, Sept. 19, 2024 /PRNewswire/ — MNML, a brand under Nutricare Pty Ltd, is dedicated to creating innovative and sustainable products. As consumers increasingly seek out products that merge effectiveness, sustainability, and wellness, MNML proudly announces the launch of its Chamomile Sleep + Calm Laundry Capsules. These innovative capsules not only clean your laundry but also enhance your sleep quality, setting a new benchmark in the eco-friendly laundry market.

MNML Product Shot

Outperforming Competitors with Superior Sleep Benefits

Unlike other laundry brands that focus solely on cleaning, MNML’s Chamomile Sleep + Calm Laundry Capsules offer more than just functionality. Infused with our proprietary SLEEPTEK™ fragrance technology, these capsules release calming aromas scientifically proven to promote relaxation and improve sleep quality. While many competitors offer eco-friendly cleaning solutions, MNML is the first to integrate sleep-enhancing benefits with powerful cleaning performance.

The Perfect Fusion of Science and Nature

MNML’s Chamomile Sleep + Calm Laundry Capsules represent a breakthrough in the connection between scent and sleep. Each capsule features a carefully crafted fragrance blend designed to create a soothing environment that helps users unwind and fall asleep more easily. But the benefits don’t end there. Our 3-in-1 formula delivers natural bio-enzymes for effective cleaning, fabric care, and a refreshing scent—all while being free from phosphates, phthalates, and chlorine.

Sustainability at Its Core

Aligned with MNML’s commitment to environmental stewardship, our Chamomile Sleep + Calm Laundry Capsules are packaged in plastic-free, recyclable cardboard tubes or plastic-free biopoly refill bags. Choosing MNML means reducing your environmental footprint without compromising on performance or quality.

"Our mission at MNML is to innovate and create products that exceed the expectations of today’s conscious consumers," said Nicole Short, Co-founder at MNML. "With our Chamomile Sleep + Calm Laundry Capsules, we’re setting a new standard in the crowded laundry market by combining superior sleep benefits with exceptional cleaning power."

A New Standard in Laundry Care

MNML is committed to redefining laundry care. Our Chamomile Sleep + Calm Laundry Capsules offer both powerful cleaning performance and sleep-enhancing benefits, all while being eco-friendly and sustainable.

Availability

The Chamomile Sleep + Calm Laundry Capsules are now available at mnmllife.com.au and select Woolworths stores nationwide.

For more information, visit mnmllife.com.au or contact [email protected].

Source : MNML Takes Sleep and Sustainability to the Next Level with New Chamomile Sleep + Calm Laundry Capsules

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

PETALING JAYA, Malaysia, Sept. 19, 2024 /PRNewswire/ — Get ready to rock out with VISTA Eye Specialist (‘VISTA’) as we celebrate our 25th Birthday with the "See The World Like A Rockstar" Eye Carnival! This event embraces the Rockstar theme, embodying our commitment to empowering individuals—employees and patients alike—to achieve clear vision. VISTA is proud to have served over 455,000 happy patients in the last 25 years.

VISTA Penang team (Air Itam and Balik Pulau) celebrating 25 years of vision with style.

Rockstar Vision and 25 Years of Excellence

To commemorate VISTA’s 25th anniversary, our centers are transformed into rockstar havens, complete with thematic decorations, photo backdrops, and a vibrant atmosphere. As Ms. Jing Wen Yap, Team Leader of this Carnival, states, "We’re committed to providing a WOW experience for every patient. From the moment they step into our centers, they’ll be immersed in a world of rockstar glamour and exceptional eye care."

To enhance this once-in-a-lifetime patient experience, we invite all to join the celebration party in their best rockstar outfit. Concurrently, we’re hosting a Rockstar Fashion Contest where patients can showcase their unique style and win exclusive Starbucks merchandise.

Carnival Highlights:

Eye screenings for common eye diseases like cataracts, glaucoma, and macular degeneration Focus on family connection: Emphasizes how quality time with loved ones promotes overall well-being Fun activities and games for all ages Health and wellness booths with valuable information and resources Goodie for kids and adults Showcase of cutting-edge vision correction: Featuring the latest in No-Blade Cataract Surgery and next-generation CLEAR shortsightedness correction Rockstar Fashion Contest Giveaway 5-Day Giveaway (September 14-18, 2024): Win exciting prizes worth up to RM1,800 in our VISTA 25th Birthday Giveaway on social media.

"We’re excited to share this milestone with our community and offer a unique experience that combines fun, education, and eye care," said Ms. Chloe Wong, Chief Marketing of VISTA. "Our goal is to raise awareness about the importance of eye health and provide accessible care to everyone."

VISTA Opens Its Brand New 18th Outlet at Kajang

We are proud to celebrate our 25th birthday with the opening of our 18th outlet in Kajang, located at MKH Boulevard II. "This milestone marks a significant step in our journey to provide accessible and affordable eye care to communities across Malaysia. Our new clinic is designed with sustainability and accessibility in mind, ensuring a welcoming and comfortable environment for all," said Ms. Chin-Ching Tan, the CEO of VISTA.

To further reach out to the Kajang community, we are hosting roadshows at local colleges, universities, and schools, offering free eye screenings. This is an opportunity to educate students on the importance of eye health and regular check-ups, helping to detect potential eye problems early and promoting overall well-being.

Join us for the VISTA 25th Birthday Eye Carnival on September 19-21, 20-22, and 27-29, 2024, and experience the rockstar lifestyle while taking care of your vision!

About VISTA Eye Specialist

VISTA Eye Specialist is more than just an eye care provider; we’re a community-driven organization dedicated to improving lives through better vision. Since 1999, our team of experienced ophthalmologists and optometrists have been committed to delivering personalized care and accessible services to patients across Malaysia. We offer superior solutions for a range of eye conditions, including cataracts and vision correction. 

Source : VISTA 25th Birthday Eye Carnival: A Rockin' Celebration of Vision and 25 Years of Excellence

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66).

PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ — Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the updated results from the cohort-G data for Osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment for the patients with advanced G/GEJ cancer (TranStar102). The updated data continues to show encouraging efficacy from previously disclosed data at ASCO 2024.

The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached 14.2 months for those with H/M CLDN18.2 expression, with a confirmed objective response rate of 68%. The vast majority of these patients are PD-L1 CPS<5.

Using the group of patients with very low or no CLDN18.2 expression as surrogate control, the HR for the triple combination is 0.505 (95% CI, 0.244-1.045) in favor of the CLDN18.2 H/M, any CPS expressers. The data corroborates the synergistic mechanism of action between CLDN18.2 targeting agent and checkpoint inhibitors reported by Transcenta last year at ESMO which showed that CLDN18.2 targeting antibody can induce PD-L1 expression in gastric cancer tumor cells (even in those with PD-L1 low or null expression) and T-cell infiltration. As of the cutoff date, the median OS was not reached because of the limited number of events, the 12-month survival rate for the overall population (82 patients) in this cohort was 73.8% (95% CI: 62.0- 82.4%).

Previous studies have found that the combination of Zolbetuximab+CAPOX in CLDN18.2 positive patients, regardless of the PD-L1 status, leads to an improvement in PFS from 6.80 to 8.21 months (HR = 0.687 (95% CI, 0.544-0.866) (Source: Shah, Manish A et al. Nature Medicine 2023 Aug 29 (8): 2133-2141). This updated Cohort-G data shows that the efficacy from the triple combo therapy of Osemitamab (TST001) plus Nivolumab and CAPOX compares very favorably with the historical data of Nivolumab plus CAPOX combination or Zolbetuximab plus CAPOX combination.

The updated data has been featured as a poster presentation (Abstract #1419p) on September 16, 2024 at the ESMO Congress 2024 in Barcelona, Spain.

"The updated data from the Cohort-G trial of Osemitamab (TST001) in combination with Nivolumab and CAPOX as first-line treatment for advanced G/GEJ cancer are highly encouraging. The confirmed objective response rate and median progression-free survival in patients with high/medium CLDN18.2 expression, known PD-L1, as compared to patients with no CLDN18.2 expression, confirm the synergy between Osemitamab (TST001) and Checkpoint inhibitors and demonstrates the potential of this triple combination therapy, potentially including in low PD-L1 expressers," said Dr. Caroline Germa, Executive Vice President, Global Medicine Development and Chief Medical Officer at Transcenta, "These results highlight the promise of Osemitamab (TST001) in improving outcomes for patients with advanced G/GEJ cancer."

"The Cohort-G data presented at ESMO 2024 provide compelling evidence of the clinical benefit of the triple combination therapy. The significant improvement in progression-free survival and objective response rate, particularly in patients with high/medium CLDN18.2 expression and low PD-L1 CPS, is a testament to the potential of this therapeutic approach," said Professor Lin Shen, Director, department of Gastrointestinal Oncology and Phase I Clinical Trial Center at Peking University Cancer Hospital; and Principal Investigator of the trial, "We are excited about the potential benefits this treatment could bring to our patients."

A brief summary of the study is as follows:

Study Design

Cohort G from Transtar102 study (NCT04495296) was designed to explore the safety and efficacy of Osemitamab (TST001) plus Nivolumab and CAPOX as first-line treatment for advanced G/GEJ cancer, with a safety lead-in and expansion phase. Patients were alternately allocated to 3 or 6mg/ kg at expansion phase. Eligible patients include HER2 negative or unknown, unresectable locally advanced or metastatic G/GEJ cancer, regardless of CLDN18.2 or PD-L1 expression. CLDN18.2 and PD-L1 status were analyzed retrospectively using IHC 14G11 LDT assay and PD-L1 IHC 28-8 pharmDx at a central laboratory. The CLDN18.2 expression was divided into three subgroups: H/ M (high/medium), L (low) and R (rest: lower or negative) according to the tumor cells showing membranous CLDN18.2 staining per CLDN18.2 IHC 14G11 LDT assay.

Encouraging ORR and mPFS

As of the cut-off date, 82 patients had been dosed with a median follow-up of 15.2 months. The exploratory analysis of the subgroup efficacy of patients in overall, overall with/known CLDN18.2/ PD-L1, and in the subgroup with PD-L1 CPS<5 is as follows:

Overall patients group: The mPFS is 12.6 months in patients with high or medium expression (H/M), 7.1 months in patients with low expression (L) and 8.5 months in the rest patients (R). Confirmed ORR was 58.1%, 52.4% and 55.6% respectively. 12 months survival rate for the overall population (n=82) is 73.8%. Overall patients with known CLDN18.2/PD-L1 (n=66): The mPFS is 14.2 months in the patients with high or medium expression (H/M), 8.5 months in patients with low expression (L) and 6.7 months in the rest patients (R). Confirmed ORR was 68.0%, 61.1% and 50.0% respectively. Subgroup with PD-L1 CPS<5 (n=56): The mPFS is 16.6 months in the patients with high or medium expression (H/M), 7.1 months in patients with low expression (L) and 5.7 months in the rest patients (R). Confirmed ORR was 71.4%, 60.0% and 47.1% respectively.

Manageable Safety Profile

All patients experienced treatment-related adverse events (TRAE). The most common TRAEs were hypoalbuminaemia, nausea and vomiting, most of them were of CTC AE grade 1 or 2 and manageable. The safety profile was similar to TST001 in combination with CAPOX which was presented previously (J Clin Oncol 41, 2023, suppl 16; abstr 4046).

About Osemitamab (TST001)

Osemitamab (TST001) is a high affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("ADCC"). It has shown potent anti-tumor activities in tumor xenograft models. Osemitamab (TST001) is the second most advanced CLDN18.2 targeting antibody being developed globally. Osemitamab (TST001) was generated using Transcenta’s Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab (TST001) kills CLDN18.2 expressing tumor cells by mechanisms of ADCC. Leveraging advanced bioprocessing technology, the fucose content of Osemitamab (TST001) was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of Osemitamab (TST001). Clinical trials for Osemitamab (TST001) are ongoing in the U.S. and China (TranStar101/NCT04396821, TranStar102/NCT04495296). Osemitamab (TST001) has been granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer.

About Transcenta

Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Princeton, US and in Beijing, Shanghai and Guangzhou of China, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing 14 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

CONTACT:

Bryan Cheng, [email protected], 15067129733

Source : Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HO CHI MINH CITY, Vietnam, Sept. 19, 2024 /PRNewswire/ — NextBold Capital, a private equity firm focused on supporting the growth of small and medium enterprises in Southeast Asia, is being recognized as a key Emerging Manager for Asia Pacific at SuperReturn Asia 2024. The firm is raising its first fund to invest in SMEs across Vietnam, Cambodia, and Laos — three fast-growing markets ripe for development.

Managing Partners of NextBold Capital: Jonas Wilbert, Sjoerd Zwinkels and Pedro Baliza.

NextBold Capital was co-founded by Sjoerd Zwinkels, former Investment Director at Mekong Capital, alongside Quadrant-backed Fitness & Lifestyle Group former executives Pedro Baliza and Jonas Wilbert, who bring extensive operational and investment experience. The firm aims to provide not just capital but hands-on operational expertise to help businesses in these markets scale sustainably.

A Different Approach: Operational Private Equity

NextBold Capital stands out for its "Operational Investing" approach: the firm actively works on-the-ground with portfolio companies to implement governance, drive revenue growth, and improve operational efficiency. NextBold’s management team has spent the last decade balancing investing with hands-on operational roles in some of Indochina’s most successful businesses.

"We’re not just investors; we’re partners on the ground," said Pedro Baliza, Managing Partner of NextBold Capital. "We get involved at an execution level, helping companies address their toughest challenges and unlock their full potential."

Indochina Focus, Regional Ambition

NextBold Capital’s strategy encompasses targeting SMEs in key urban centers across Vietnam, Cambodia, and Laos — markets experiencing rapid growth due to a rising middle class, strong entrepreneurial cultures, and increased foreign investment. The firm focuses on sectors like education, healthcare, consumer goods, and services, where they see opportunities for governance transformation and value creation.

"These markets are still underserved by global investors, particularly in the SME space. We see enormous potential for value creation by bringing in the right mix of capital and operational support," said Sjoerd Zwinkels, Managing Partner.

$100M Fundraising to Drive Growth

NextBold Capital’s inaugural $100 million fund, designed to fuel growth for SMEs across Southeast Asia, has seen its fundraising efforts ramp up mid this year. Its unique positioning has granted the firm a flurry of interest from investors, and now an early recognition in the form of shortlisting as a "must-watch" Emerging Private Equity Manager for APAC at SuperReturn Asia 2024, one of the World’s leading private equity and venture capital conferences.

With several family offices already committed, the fund has started mapping the market in a number of sectors including education and healthcare, with pre-funding deals already in motion.

"We’re incredibly excited about the deals we’ve already lined up. Our early investments are targeting companies with strong business fundamentals in fast-growing markets, where we see clear potential for sector dominance with the right operational support," said Pedro Baliza, Managing Partner. "We’re seeing great momentum from family offices and other co-investors, and are ready to capitalize on the immense growth opportunities ahead."

About NextBold Capital

NextBold Capital is a private equity firm based in Ho Chi Minh City, Vietnam, with a focus on growing SMEs across Southeast Asia through both capital investment and operational support.

The firm’s $100 million inaugural fund will invest in businesses across education, healthcare, consumer goods, technology, and agribusiness in Vietnam, Cambodia, and Laos. By providing on-the-ground expertise and fostering sustainable growth, NextBold Capital aims to elevate businesses to global competitiveness.

Contact:

Pedro Baliza
Managing Partner
NextBold Capital 
Email: [email protected] 
Website: www.nextboldcap.com

Source : NextBold Capital Eyes $100M Fund to Back SMEs in Vietnam, Cambodia, and Laos

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Sept. 19, 2024 /PRNewswire/ — Watson-Marlow Fluid Technology Solutions (WMFTS), a world leader in manufacturing peristaltic pump and associated fluid path technologies for process industries and life sciences, has announced the launch of Qdos™ H-FLO chemical metering and dosing pump for higher flow rates and WMArchitectTM single-use solutions to offer a wide range of biopharmaceutical fluid management innovations from a single, secure supplier.

WMArchitectTM innovating fluid solutions for biopharmaceutical and Qdos™ for chemical industries.

Jacky Chan, Divisional Director Asia–Pacific of Watson-Marlow Fluid Technology Solutions, commented, "The two newly launched products are a testament to our commitment in prioritising our customers’ needs through constant innovation. With our 13 sales offices in APAC, we position ourselves close to our APAC customers by providing innovative, simple to use and cost-effective solutions. Helping our customers to achieve net zero target for sustainability is one of our central tenets. The high accuracy and repeatability of our pumps helps customers to achieve cost savings in chemical usage that assists them to move towards net zero targets. By making the chemical dosing simpler and efficient for operations, maintenance and EHS teams, Qdos H-FLO offers several onboard communication options for SCADA and PLC integration to achieve process optimisation."

Qdos™ H-FLO

The recent launch of Qdos™ H-FLO features up to 600 L/h and pressure capability up to 7 bar (102 psi), making chemical dosing simpler and cost effective and serves a wide variety of applications and industries, such as water and wastewater treatment, mining and mineral processing, chemical applications in food and beverage or pulp and paper. With higher flow rates combined with a variety of pumpheads to ensure chemical compatibility with the process fluid, the Qdos H-FLO high-precision pump offers flexibility to be scalable with a customer’s process.

Qdos H-FLO also cuts costs through higher precision chemical metering, with an accuracy of ±1% and repeatability of ±0.5% in dosing. Qdos H-FLO will bring benefits to applications including disinfectants, coagulants, flocculants, acids/alkalis, mining reagents and surfactants.

Qdos H-FLO is supported with an optional pressure sensing kit that provides real-time pressure monitoring, which ensures process security and improves safety. The optional pressure sensing kit comes with configurable alarms for process monitoring and is compatible with commonly used chemicals in process industries.

Benefits:

RFID Pump head detection ensures confirmation of correct pumphead Revolution counter for pump head service maintenance Leak detection and fluid containment prevent spills and chemical exposure upon pumphead expiry Network integration, control and communication options include EtherNet/IP, PROFINET and PROFIBUS for easy integration with SCADA / PLC One common pump drive with several pump head options for changing process conditions and chemistries

WMArchitectTM 

To streamline the process, safeguard products, and reduce regulatory burden for biopharmaceutical companies, the new range of WMArchitect single-use solutions is designed to offer both standard, ready-to-use single-use assemblies as well as customised designs with an open architecture approach. WMArchitect is a new end-to-end, single-use fluid path management solution consisting of customised designs – single-use assemblies, single-use fluid transfer assemblies, fill/finish single-use assemblies, and validation testing.

All WMArchitect single-use solutions are manufactured, pre-assembled and packaged at WMFTS’ global network of state-of-the-art Class 7 cleanrooms. The WMFTS global supply network provides uninterrupted supply security and robust lead times. To ensure easy deployment and meet the requirements set by current good manufacturing practice (cGMP) guidelines, lot traceability of each component can be made available as part of our detailed documentation. 

Jacky Chan further elaborated. "WMArchitect is ideal for high purity biopharmaceutical process development, clinical trials and small to large scale production batches. As the most critical component for maximising performance is where the tubing meets the pump, our assembly solutions are designed synergistically with our best-in-class Watson-Marlow peristaltic pump technologies and filling solutions to ensure reliable, repeatable performance for your most sensitive processes."

Benefits:

Designed to reduce a biopharmaceutical company’s validation burden Support of internal validation protocols Flexible integration with an open architecture approach Use in conjunction with Watson-Marlow peristaltic pumps or Flexicon filling systems for an end-to-end fluid management solution Supply security with WMFTS’ global manufacturing and supply network

About Watson-Marlow Fluid Technology Solutions

Watson-Marlow Fluid Technology Solutions (WMFTS) is a world leader in manufacturing peristaltic pumps and associated fluid path technologies for the life sciences and process industries. The company offers a wide range of peristaltic pumps and associated fluid path technologies, including tubing, specialised filling systems and products for single-use applications. There are six pumps in the Qdos range from WMFTS—20, 30, 60, 120, CWT and H-FLO—to fulfil all your chemical metering and dosing requirements.

WMFTS is part of Spirax Group, with operations in 42 countries.

Further information can be found at www.wmfts.com.

Source : Watsons-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network